Hologic, Inc. (NASDAQ:HOLX - Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as $58.30 and last traded at $58.45, with a volume of 3303816 shares trading hands. The stock had previously closed at $61.27.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the company. Evercore ISI cut their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research report on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Stephens reissued an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Royal Bank of Canada reduced their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 6th. Finally, Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Hologic currently has an average rating of "Hold" and a consensus target price of $84.62.
Read Our Latest Analysis on HOLX
Hologic Stock Performance
The firm has a market cap of $12.98 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 2.14 and a beta of 0.82. The stock's fifty day moving average is $62.47 and its two-hundred day moving average is $71.55. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Hologic
A number of hedge funds and other institutional investors have recently modified their holdings of HOLX. General Partner Inc. bought a new stake in shares of Hologic during the 4th quarter worth about $26,000. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co increased its position in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares during the period. 94.73% of the stock is currently owned by institutional investors.
About Hologic
(
Get Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
